Making Vaccines Accessible
Despite the challenges and high cost of development, vaccine innovation is at an all-time high, as new approaches aim to improve global access.
Vaccines have had a tremendous impact on human quality of life, increasing life expectancies by eradicating deadly diseases. The cost of developing and manufacturing vaccines remains extremely high, however. Given unprofitable prices, improving access to vaccines has been a major challenge. Despite these problems, innovation is reaching a new level, while new approaches to manufacturing and distribution involving non-government organizations and contract manufacturers offshore have helped improve access. This article touches on some of the innovations, and the types of business models that have made them possible, and includes an interview with the director of the Sabin Institute.
Download
Pharmaceutical Technology and BioPharm International’s 2017 Vaccine Development and Manufacturing 2017eBook.
Article Details
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 4–10
Citation
When referring to this article, please cite it as A. Shanley, "Making Vaccines Accessible," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
